East Hills, NY (March 12, 2009) -- Pall Corporation (NYSE: PLL) and SPF Innovations LLC (Watertown, Massachusetts) have announced that Pall acquired an exclusive license to manufacture, market and sell SPF™ Technology for biopharmaceutical applications.
Single Pass TFF (SPTFF) is a new form of tangential-flow filtration (TFF) delivering high-conversion separations without a recirculation loop, providing the performance of TFF with the simplicity of direct-flow filtration. SPTFF delivers multiple economic benefits, important operational benefits and new capabilities such as increased yield, lower hold-up volume, very high concentration factors and low exposure time. SPTFF is integrated easily with other downstream processes, such as chromatography and virus removal.
Pall will preview SPTFF technology at INTERPHEX 2009, the world’s largest pharmaceutical conference and exhibition, at New York City’s Jacob K. Javits Convention Center, March 17-19.
SPTFF technology is protected by U.S. Patent No. 7,384,549.
About Pall Corporation
Pall Corporation is the global leader in the field of filtration, separation and purification. Pall is organized into two businesses: Life Sciences and Industrial. These businesses provide leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, energy, electronics, water purification, aerospace, transportation and broad industrial markets. Total revenues for fiscal year 2008 were $2.6 billion. The Company is headquartered in East Hills, New York and has extensive operations around the world. For more information visit Pall at http://www.pall.com .
About SPF Innovations
SPF Innovations LLC is a privately held bioseparations R&D company developing bioprocessing and bioanalytical products to meet the manufacturing and sample-prep needs of biopharmaceutical companies, life science researchers and drug development scientists.